

## Learner Notification

### MED Learning Group

#### Precision Medicine in NSCLC: Novel Targets for Effective Management

July 31, 2023 – July 31, 2024

Online

#### Acknowledgement of Financial Commercial Support

AstraZeneca, Daiichi Sankyo, Inc.

#### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

#### Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

#### Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

#### Objectives - After Attending This Program You Should Be Able To

1. Describe the role of TROP2 in the clinicopathophysiology of NSCLC and its role in treatment as a targetable protein.
2. Assess the clinical trials data for TROP2-targeted therapy, in the second-line, for those patients with relapsed/refractory NSCLC.
3. Identify strategies for managing adverse events, patient and treatment selection that include TROP2-directed ADCs.

#### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Matthew	Frese	NA
Christina	Gallo	NA
Teresa L.	Keating	NA
Alexis	Klinger	NA
Lisa	Kuhns	NA
Nicole	Longo	NA
Marissa	Mays-Verman	NA
Julia K.	Rotow	AstraZeneca, AbbVie, Gritstone bio, Lilly, Takeda, Sanofi Genzyme, Genentech, Guardant Health, BioAtla, Summit Therapeutics, G1 Therapeutics: Consultant, Bicycle Therapeutics, EpimAb Biotherapeutics, Enliven Therapeutics, Daiichi Sankyo, ORIC, BioAtla, AstraZeneca, AbbVie,

		Blueprint Medicines, RedCloudBio, Loxo Oncology, Duality Biologics: Contracted Research, AstraZeneca: Honoraria
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)